Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c-KIT, and RET Anti-Targets.

ChemMedChem - 2 Jan 2024

Akwata Desmond, Kempen Allison L, Dayal Neetu, Brauer Nickolas R, Sintim Herman O

Abstract excerpt

FLT3 is mainly expressed in immune and various cancer cells and is a drug target for acute myeloid leukemia (AML). Recently, FLT3 has also been identified as a potential target for treating chronic pain. Most FLT3 inhibitors (FLT3i) identified to date, including approved drugs such as gilteritinib, midostaurin, ponatinib, quizartinib, and FLT3i in clinical trials, such as quizartinib and crenolanib, also inhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Chronic Pain

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Source

Identifiers

PMID: 37971283
DOI: 10.1002/cmdc.202300442

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c-KIT, and RET Anti-Targets.PMID 37971283Read ↗

FLT3 Inhibitors for Treating Acute Myeloid Leukemia.Semantic proximity Read ↗

Recent Advances in FLT3 Inhibitors for Acute Myeloid LeukemiaSemantic proximity Read ↗

Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.Semantic proximity Read ↗

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.Semantic proximity Read ↗

Novel FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.Semantic proximity Read ↗

Investigational drugs targeting FLT3 for leukemia.Semantic proximity Read ↗

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel ApproachesSemantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Strategies targeting FLT3 beyond the kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.